Royalty Pharma
Industry leader in investing in marketed and late stage biopharmaceutical products
Business Model:
Revenue: $2.2B
Employees: 51-200
Rankings
Industries / Tags:
Detailed Royalty Pharma Information
Geographic Data
Address: 110 E 59th Street
City: New York
State: NY
Zip: 10022
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$9B
Social
Linkedin
Crunchbase
Metrics
2,815,331Website Global Rank
6,201Website Monthly Traffic
Twitter Followers
Description
Royalty Pharma has created a rapidly growing company within the biopharmaceutical industry through the acquisition of revenue producing intellectual property – principally, royalty interests in marketed and late stage development biopharmaceutical products. Royalty Pharma does not discover, develop, manufacture or market products. Instead, the Company provides liquidity to royalty owners and assumes the future risks and rewards of ownership. Royalty Pharma has been working with research institutions, inventors and biotechnology &a; pharmaceutical companies since 1996, and now owns royalty interests in forty four approved and marketed biopharmaceutical products and seven products in clinical trials and/or under review with the United States Food and Drug Administration (“FDA”) and/or the European Medicines Agency ("EMA”).
Contact Phone:
+12128830200
Contact Email:
Royalty Pharma went public on 6/18/2020 on the NASDAQ
Listed Exchange:
NASDAQ
IPO Date:
6/18/2020
IPO Valuation:
$17B
Ticker Symbol:
RPRX
IPO Price:
$28/share
Amount Raised:
$2B
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2022 | Cytokinetics | Post-IPO Debt | 0 |
| 5/2022 | ApiJect | Private Equity Round | 0 |
| 11/2021 | BioCryst Pharmaceuticals | Post-IPO Equity | 0 |
| 12/2020 | BioCryst Pharmaceuticals | Post-IPO Debt | 0 |
| 11/2019 | Epizyme | Post-IPO Equity | 0 |
| 7/2022 | Cytokinetics | Post-IPO Debt | 0 |
| 5/2022 | ApiJect | Private Equity Round | 0 |
| 11/2021 | BioCryst Pharmaceuticals | Post-IPO Equity | 0 |
| 12/2020 | BioCryst Pharmaceuticals | Post-IPO Debt | 0 |
| 11/2019 | Epizyme | Post-IPO Equity | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
